Increased expression of TGF-β1 in the sclerotic skin in bleomycin- 'susceptible' mouse strains

Journal of Medical and Dental Sciences

Volumn 51, Issue 1, 2004, Pages 7-17

  Oi, Mieko ^a   Yamamoto, Toshiyuki ^a   Nishioka, Kiyoshi ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Bleomycin; Model mouse; Mouse strain; Scleroderma; Transforming growth factor

Indexed keywords

BLEOMYCIN; COLLAGEN; MESSENGER RNA; TGFB1 PROTEIN, MOUSE; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; BIOSYNTHESIS; C3H MOUSE; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DBA MOUSE; DISEASE MODEL; DISEASE PREDISPOSITION; FEMALE; FIBROBLAST; GERMFREE ANIMAL; MACROPHAGE; METABOLISM; MOUSE; MOUSE STRAIN; SKIN; SPLEEN; SYSTEMIC SCLEROSIS;

ANIMALS; BLEOMYCIN; COLLAGEN; DISEASE MODELS, ANIMAL; DISEASE SUSCEPTIBILITY; FEMALE; FIBROBLASTS; GERM-FREE LIFE; MACROPHAGES; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, INBRED DBA; MICE, INBRED STRAINS; RNA, MESSENGER; SCLERODERMA, SYSTEMIC; SKIN; SPLEEN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

EID: 3042822469     PISSN: 13428810     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Krieg T, Meurer M. Systemic scleroderma. Clinical and pathophysiologic aspects. J Am Acad Dermatol 1988;18:457-81.
2. LeRoy EC, Black C, Fleishmajer R. et al. Scleroderma (systemic sclerosis): Classificaion, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
3. Varga J, Rudnicka L, Uitto J. Connective tissue alterations in systemic sclerosis. Clin Dermatol 1994;12:387-96.
4. Umezawa H, Maeda K, Takeuchi T. et al. New antibiotics, bleomycin A and B. J Antibiot 1966;19:200-9.
5. Cohen IS, Mosher MB, O'Keefe EJ. et al. Cutaneous toxicity of bleomycin in therapy. Arch Dermatol 1973;107:553-5.
6. Nixon DW, Pirozzi D, York RM. Dermatologic changes after systemic cancer therapy. Cutis 1981;27:181-94.
7. Yamamoto T, Yokozeki H, Nishioka K. Dermal sclerosis in the lesional skin of 'flagellate' erythema (scratch dermatitis) induced by bleomycin. Dermatology 1998;297:399-400.
8. Surville-Barland J, Caumes E, Ankri A. et al. Bleomycin-induced digital gangrene. Eur J Dermatol 1998;8:221.
9. Finch WR, Rodnan GP, Buckingham RB. et al. Bleomycin-induced scleroderma. J Rheumatol 1980;7:651-9.
10. Kerr LD, Spiera H. Scleroderma in association with the use of bleomycin: a report of 3 cases. J Rheumatol 1992;19:294-6.
11. Passiu G, Cauli A, Atzeni F. et al. Bleomycin-induced scleroderma: report of a case with a chronic course rather than the typical acute/subacute self-limiting form. Clin Rheumatol 1999;18:442-4.
12. Yamamoto T, Takagawa S, Katayama I. et al. Animal model of sclerotic skin. I : Local injections of bleomycin induce sclerotic skin mimicking scleroderma. J Invest Dermatol 1999;112:456-62.
13. V mice. J Rheumatol 1999;26:2628-34.
14. Yamamoto T, Kuroda M, Nishioka K. Animal model of sclerotic skin. III : Histopathological comparison of bleomycin-induced scleroderma in various mice strains. Arch Dermatol Res 2000;292:535-41.
15. Yamamoto T, Nishioka K. Animal model of sclerotic skin. IV: Induction of dermal sclerosis by bleomycin is T cell independent. J Invest Dermatol 2001;117:999-1001.
16. Yamamoto T, Nishioka K. Animal model of sclerotic skin. V: Increased expression of α-smooth muscle actin in fibroblastic cells in bleomycin-induced scleroderma. Clin Immunol 2002;102:77-83.
17. Fanning GC, Welsh KI, Bunn C. et al. HLA associations in three mutually exclusive autoantibody subgroups in UK systemic sclerosis patients. Br J Rheumatol 1998;37:201-7.
18. Arnett FC. HLA and autoimmunity in scleroderma. Int Rev Immunol 1995;12:107-28.
19. Rihs HP, Conrad K, Mehlorn J. et al. Molecular analysis of HLA-DPB1 alleles in idiopathic systemic sclerosis and uranium miners with systemic sclerosis. Int Arch Allergy Immunol 1996;109:216-22.
20. Falkner D, Wilson J, Medsger TA. et al. HLA and clinical associations in systemic sclerosis patients with anti-Th/To antibodies. Arthritis Rheum 1998;41:74-80.
21. Kuwana M, Kaburaki J, Okano Y. et al. The HLA-DR and DQ genes control the autoimmune response to DNA topoiso merase I in systemic sclerosis (scleroderma). J Clin Invest 1993;92:1296-301.
22. Lambert NC, Evans PC, Hashizumi TL. et al. Persistent fetal microchimerism in T lymphocytes in associated with HLA-DQA1*0501: implications in autoimmunity. J Immunol 2000;164:5545-8.
23. Lambert NC, Distler O, Mullar-Ladner U. et al. HLA-DQA1 *0501 is associated with systemic sclerosis in Caucasian men. Arthlitis Rheum 2000;43:2005-10.
24. Tan FK, Stivers DN, Arnett FC. et al. HLA haplotypes and microsatellite polymorphism in and around the MHC region in a Native American population with a high prevalence of scleroderma (systemic sclerosis). Tissue Antigens 1999;53:74-80.
25. Vargas-Alarcon G, Granados J, Ibanez G. et al. Association of HLA-DR5(DR11) with systemic sclerosis (scleroderma) in Mexican patients. Clin Exp Rheumatol 1995;13:11-6.
26. Roberts AB, Sporn MB, Assoian RK. et al. Transforming growth factor type β: Rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA 1886;83:4167-71.
27. Sporn MB, Roberts AB. Transforming growth factor-β: Recent progress and new challenge. J Cell Biol 1992;119:1017-21.
28. Grande JR Role of transforming growth factor-β in tissue injury and repair. Proc Soc Exp Biol Med 1997;214:27-40.
29. Kulozik M, Hogg A, L-Buttgereit B. et al. Co-localization of transforming growth factor-β2 with α1(I) procollagen mRNA in tissue sections of patients with systemic sclerosis. J Clin Invest 1990;86:917-22.
30. Peltonen M, Kahari L, Jaakkola S. et al. Evaluation of transforming growth factor-β and type I procollagen gene expression in fibrotic skin diseases by in situ hybridization. J Invest Dermatol 1990;94:365-71.
31. Gruschwitz M, Muller P, Sepp N. et al. Transcription and expression of transforming growth factor type beta in the skin of progressive systemic sclerosis: a mediator of fibrosis? J Invest Dermatol 1990;94:197-203.
32. Arimura M, Yokozeki H, Katayama I. et al. Experimental study for the development of an in vitro test for contact allergens. Int Arch Allergy Immunol 1998;115:228-34.
33. Yamamoto T, Nishioka K. Analysis of the effect of halofuginone on bleomycin-induced scleroderma. Rheumatology 2002;41:594-6.
34. Breen E, Shull S, Burne S. et al. Bleomycin regulation of transforming growth factor-β mRNA in rat lung fibroblasts. Am J Respir Cell Mol Biol 1992;6:146-52.
35. Yamamoto T, Eckes B, Krieg T. Bleomycin increases steady-state levels of type I collagen, fibronectin and decorin mRNAs in human skin fibroblasts. Arch Dermatol Res 2000;292:556-61.
36. Yamamoto T, Takagawa S, Katayama I. et al. Anti-sclerotic effect of transforming growth factor-β antibody in a mouse model of bleomycin-induced scleroderma. Clin Immunol 1999;92:6-13.